These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7214334)

  • 1. Lysozyme enhancement of tumor cell immunoprotection in a murine fibrosarcoma.
    Warren JS; Rinehart JJ; Zwilling BS; Neidhart JA
    Cancer Res; 1981 May; 41(5):1642-5. PubMed ID: 7214334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-specific and allospecific immunogenicity of soluble extracts from chemically induced murine sarcomas.
    Pellis NR; Tom BH; Kahan BD
    J Immunol; 1974 Aug; 113(2):708-11. PubMed ID: 4136043
    [No Abstract]   [Full Text] [Related]  

  • 3. Alteration of immunogenicity of xenogenized tumor cells in syngeneic rats by the immune responses to virus-associated antigens produced on immunizing cells.
    Hosokawa M; Okayasu T; Ikeda K; Katoh H; Suzuki Y; Kobayashi H
    Cancer Res; 1983 May; 43(5):2301-5. PubMed ID: 6831454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.
    Daftarian P; Song GY; Ali S; Faynsod M; Longmate J; Diamond DJ; Ellenhorn JD
    Cancer Res; 2004 Aug; 64(15):5407-14. PubMed ID: 15289349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suramin has adjuvant properties and promotes expansion of antigen-specific Th1 and Th2 cells in vivo.
    Denkinger M; Shive CL; Pantenburg B; Forsthuber TG
    Int Immunopharmacol; 2004 Jan; 4(1):15-24. PubMed ID: 14975356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The antigenicity and immunogenicity of cell-free extracts of chemically induced murine sarcomas.
    Pilch YH
    Cancer Res; 1968 Dec; 28(12):2502-11. PubMed ID: 4302533
    [No Abstract]   [Full Text] [Related]  

  • 7. IFN-gamma- and cell-to-cell contact-dependent cytotoxicity of allograft-induced macrophages against syngeneic tumor cells and cell lines: an application of allografting to cancer treatment.
    Yoshida R; Yoneda Y; Kuriyama M; Kubota T
    J Immunol; 1999 Jul; 163(1):148-54. PubMed ID: 10384111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant.
    Sturmhoefel K; Lee K; Gray GS; Thomas J; Zollner R; O'Toole M; Swiniarski H; Dorner A; Wolf SF
    Cancer Res; 1999 Oct; 59(19):4964-72. PubMed ID: 10519410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transplantation resistance to mouse ependymoblastoma following immunization with dehistonized syngeneic tumor chromatin.
    Anderson KM; Lo J; Mirakian A; Kellen JA
    Cancer Res; 1976 Jun; 36(6):1935-40. PubMed ID: 1268848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specificity of homograft rejection in vivo, assessed by inoculation of artificially mixed compatible and imcompatible tumor cells.
    Klein E; Klein G
    Cell Immunol; 1972 Sep; 5(1):201-8. PubMed ID: 5078988
    [No Abstract]   [Full Text] [Related]  

  • 11. Cross-reactive cellular and humoral immunity to carcinogen-induced chicken fibrosarcomas. II. Effect of prior immunization with transplantable tumors on primary tumor incidence.
    Edelman AS; Xue B; Galton JE; Sanchez P; Thorbecke GJ
    J Immunol; 1985 Sep; 135(3):2213-9. PubMed ID: 3926899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concomitant immunity and specific desensitization in murine tumor hosts.
    Vaage J
    Isr J Med Sci; 1973 Mar; 9(3):332-43. PubMed ID: 4710041
    [No Abstract]   [Full Text] [Related]  

  • 13. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine.
    Anderson LD; Petropoulos D; Everse LA; Mullen CA
    Cancer Res; 1999 Apr; 59(7):1525-30. PubMed ID: 10197624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics of the plasmacellular reaction in the draining lymph node of mice bearing the BP-8 fibrosarcoma.
    Stanislawski L; Stanislawski M
    Cancer Res; 1976 Sep; 36(9 pt.1):3020-4. PubMed ID: 975071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efferent enhancement of a methylcholanthrene-induced sarcoma transplantable in strain 13 guinea pigs.
    Berczi I; Tsay HM; Sehon AH
    Eur J Immunol; 1976 Jun; 6(6):453-5. PubMed ID: 991912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Local IL-4 delivery enhances immune reactivity to murine tumors: gene therapy in combination with IL-2.
    Pippin BA; Rosenstein M; Jacob WF; Chiang Y; Lotze MT
    Cancer Gene Ther; 1994 Mar; 1(1):35-42. PubMed ID: 7621236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of graft-versus-leukemia (GVL) effect without graft-versus-host disease (GVHD) by pretransplant donor treatment with immunomodulators.
    Morecki S; Yacovlev E; Gelfand Y; Shabat Y; Slavin S
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):406-15. PubMed ID: 19285627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hybrid resistance to the ascites form of the murine sarcoma.
    Płytycz B; Seljelid R
    Arch Immunol Ther Exp (Warsz); 1987; 35(6):863-9. PubMed ID: 3508043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Heterogeneity of murine sarcoma cells for transplantability due to their different susceptibilities to the lytic action of macrophages].
    Ustinov AS; Lavrovskiĭ VA
    Biull Eksp Biol Med; 1988 Mar; 105(3):322-4. PubMed ID: 3349171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of soluble murine histocompatibility antigens.
    Sagi S; Turianskyj FH; Gyenes L
    Immunol Commun; 1974; 3(1):85-94. PubMed ID: 4823533
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.